Natha Cristina, Vemulapalli Varun, Thosani Nirav
Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Department of Surgery and Interventional Gastroenterology, The University of Texas Health Science Center and McGovern School of Medicine, Houston, TX 77030, USA.
Cancers (Basel). 2025 Aug 29;17(17):2843. doi: 10.3390/cancers17172843.
Cholangiocarcinoma is a rare, highly aggressive malignancy of the hepatobiliary tract with poor prognosis, often diagnosed at advanced stages when curative surgical resection is not feasible. Management increasingly relies on advanced endoscopic interventions to address malignant biliary obstruction and improve clinical outcomes. Beyond conventional biliary stenting, adjunctive endoscopic ablation therapies have emerged as promising strategies to improve both stent patency and survival. This review comprehensively examines the evolving role of radiofrequency ablation and photodynamic therapy in the treatment of unresectable cholangiocarcinoma. Radiofrequency ablation utilizes localized thermal energy to induce coagulative tumor necrosis and offers advantages including procedural simplicity, favorable safety profile, and cost-effectiveness; however, its efficacy may be limited by tumor size, location, and proximity to critical structures. In contrast, photodynamic therapy employs light-activated photosensitizers to selectively induce cytotoxicity in malignant tissue, demonstrating superior outcomes in prolonging both stent patency and overall survival across multiple studies and meta-analyses. Photodynamic therapy's ability to treat more diffuse and peripheral lesions represents an important advantage, though its use is limited by photosensitivity reactions and shallow tissue penetration. Ultimately, endoscopic ablation therapies represent valuable adjunctive options in the multidisciplinary care of patients with unresectable cholangiocarcinoma. As technological advances continue and more comparative data emerge, optimized patient selection and individualized integration of these therapies hold potential to significantly improve outcomes in this challenging malignancy.
胆管癌是一种罕见的、侵袭性很强的肝胆道恶性肿瘤,预后较差,通常在无法进行根治性手术切除的晚期阶段才被诊断出来。治疗越来越依赖先进的内镜干预措施来解决恶性胆管梗阻并改善临床结局。除了传统的胆管支架置入术,辅助性内镜消融治疗已成为改善支架通畅性和生存率的有前景的策略。本综述全面探讨了射频消融和光动力疗法在不可切除胆管癌治疗中不断演变的作用。射频消融利用局部热能诱导肿瘤发生凝固性坏死,具有操作简单、安全性良好和成本效益高等优点;然而,其疗效可能受到肿瘤大小、位置以及与关键结构的距离的限制。相比之下,光动力疗法采用光激活的光敏剂在恶性组织中选择性地诱导细胞毒性,多项研究和荟萃分析表明,在延长支架通畅时间和总体生存期方面,光动力疗法具有更优的效果。光动力疗法能够治疗更弥漫和外周的病变,这是一个重要优势,不过其应用受到光敏反应和组织穿透浅的限制。最终,内镜消融治疗是不可切除胆管癌患者多学科治疗中有价值的辅助选择。随着技术不断进步以及更多比较数据的出现,优化患者选择并对这些疗法进行个体化整合,有望显著改善这种具有挑战性的恶性肿瘤的治疗效果。